B
Brian Granda
Researcher at Novartis
Publications - 26
Citations - 1015
Brian Granda is an academic researcher from Novartis. The author has contributed to research in topics: Chimeric antigen receptor & Antigen. The author has an hindex of 8, co-authored 22 publications receiving 789 citations. Previous affiliations of Brian Granda include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu,Shuguang Jiang,Chongyun Fang,Shiyu Yang,Devvora Olalere,Edward Pequignot,Alexandria P. Cogdill,Na Li,Melissa Ramones,Brian Granda,Li Zhou,Andreas Loew,Regina M. Young,Carl H. June,Yangbing Zhao +14 more
TL;DR: The use of affinity-tuned scFvs offers a strategy to empower wider use of CAR T cells against validated targets widely overexpressed on solid tumors, including those considered undruggable by this approach.
Journal ArticleDOI
Methylation of p53 by Set7/9 Mediates p53 Acetylation and Activity In Vivo
Julia K. Kurash,Hong Lei,Qiong Shen,Wendy L. Marston,Brian Granda,Hong Fan,Daniel Wall,En Li,François Gaudet +8 more
TL;DR: The first genetic evidence demonstrating that lysine methylation of p53 by Set7/9 is important for p53 activation in vivo is provided and a mechanistic link between methylation and acetylation ofp53 through Tip60 is suggested.
Patent
Regulatable chimeric antigen receptor
Jennifer Brogdon,Boris Engels,David J. Glass,Brian Granda,John Hastewell,Andreas Loew,Joan Mannick,Michael C. Milone,Leon Murphy,William Raj Sellers,Huijuan Song,Brian Edward Vash,Jan Weiler,Qilong Wu,Li Zhou +14 more
TL;DR: In this article, the authors present a comparison and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response.
Journal ArticleDOI
Interaction with both ZNRF3 and LGR4 is required for the signalling activity of R‐spondin
Yang Xie,Raffaella Zamponi,Olga Charlat,Melissa Ramones,Susanne E. Swalley,Xiaomo Jiang,Daniel S Rivera,William R. Tschantz,Bo Lu,Lisa Quinn,Christopher A. Dimitri,Jefferson Parker,Doug Jeffery,Sheri K. Wilcox,Mike Watrobka,Peter LeMotte,Brian Granda,Jeffrey A. Porter,Vic E. Myer,Andreas Loew,Feng Cong +20 more
TL;DR: The results support a dual receptor model of R‐spondin action, where LGR4/5 serve as the engagement receptor whereas ZNRF3/RNF43 function as the effector receptor.
Journal ArticleDOI
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
Nathan Singh,Noelle V. Frey,Boris Engels,David M. Barrett,Olga Shestova,Pranali Ravikumar,Katherine D. Cummins,Yong Gu Lee,Raymone Pajarillo,Inkook Chun,Amy Shyu,Steven Highfill,Andrew Price,Linlin Zhao,Liaomin Peng,Brian Granda,Melissa Ramones,Xueqing Maggie Lu,David A. Christian,Jessica Perazzelli,Simon F. Lacey,Nathan H. Roy,Janis K. Burkhardt,Florent Colomb,Mohammad Damra,Mohamed Abdel-Mohsen,Ting Liu,Dongfang Liu,Daron M. Standley,Regina M. Young,Jennifer Brogdon,Stephan A. Grupp,Carl H. June,Shannon L. Maude,Saar Gill,Marco Ruella +35 more
TL;DR: In this article, the authors present the composite outcomes of two pilot clinical trials ( NCT02588456 and NCT02650414 ) of T cells bearing a 4-1BB-based, CD22-targeting CAR in patients with relapsed or refractory ALL.